secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001628280-25-048525
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1
-------------------------------------------------------------------------------

- Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.
- Operating expenses $401.2M (R&D $174M incl upfront for CSPC, SG&A $209.1M).
- Cash $1.1B; licensed global rights to oral GLP-1 (MGL-2086) from CSPC; clinic entry H1 2026.
- New Orange Book patent for Rezdiffra covering weight-threshold dosing into 2045.
- Launched Rezdiffra in Germany after EC conditional approval in August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/0001628280-25-048525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/mdgl-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-048525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer